cpe reduction assay  (ATCC)

Journal: Health Security

Article Title: Lessons Learned From Limited Overlap of 15 In Vitro COVID-19 Drug Repurposing Screens

doi: 10.1089/hs.2022.0132

Figure Lengend Snippet: Overview of Experimental Conditions and Confirmation Assays Carried Out by Each of the Studies Reviewed

Article Snippet: Mirabelli , Huh7 , SARS-CoV-2 USA-WA1/2020 , 0.2 , Cell morphology and SARS-CoV-2 immunostaining , 4 hours preinfection , 48 hours , Multi-cycle CPE reduction assay, synergy with remdesivir, validation in iAECs.

Techniques: Infection, Incubation, Immunostaining, Activity Assay, Variant Assay, Enzyme-linked Immunosorbent Assay

Journal: Microorganisms

Article Title: Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors

doi: 10.3390/microorganisms9040734

Figure Lengend Snippet: Optimization of a CPE-reduction antiviral assay. ( A ) Percentage CPE and ( B ) Z’ value per MAYV inoculum in different cell lines (Vero, BHK, Huh-7, CRL2522 and A549 cells). Results were obtained with the MTS/PMS read-out method. Mean values ± standard deviations (SD) are shown of 3 independent experiments. CPE, cytopathogenic effect; PFU, plaque-forming unit. ( C ) Z’ value for three different MAYV inocula (MOI 0.01, 0.005, 0.001) on Vero cells. Data are presented as box plots showing individual and mean values of four independent experiments. MOI, multiplicity of infection.

Article Snippet: To determine the best cell line and the optimal MOI for the CPE reduction assay, cell viability was assessed using the MTS/PMS method as described by the manufacturer (Promega, Leiden, The Netherlands).

Techniques: Antiviral Assay, Infection

Journal: Microorganisms

Article Title: Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors

doi: 10.3390/microorganisms9040734

Figure Lengend Snippet: In vitro antiviral effect of EIDD-1931, favipiravir, suramin and ribavirin in Vero cells. ( A ) Dose–response effect of EIDD-1931, favipiravir, suramin and ribavirin on MAYV-induced CPE (MOI 0.01), quantified in Vero cells by the MTS/PMS method. Data shown are mean values ± standard deviations (SD) from three independent experiments. ( B – E ) The effect of different concentrations of ( B ) EIDD-1931, ( C ) favipiravir, ( D ) suramin and ( E ) ribavirin on the release of MAYV particles by infected Vero cells (MOI 0.01). Both viral RNA (genome copies/mL; blue) and infectious progeny virus (TCID 50 /mL; orange) were quantified at 48 h pi by real-time qRT-PCR and end-point titrations, respectively. Data shown are mean values ± SD from three independent experiments. Significant differences from untreated virus control were analyzed by Kruskal–Wallis test (*, p < 0.05; **, p < 0.005). CPE, cytopathogenic effect; TCID, tissue culture infectious dose; VC, virus control (untreated); LOD, limit of detection.

Article Snippet: To determine the best cell line and the optimal MOI for the CPE reduction assay, cell viability was assessed using the MTS/PMS method as described by the manufacturer (Promega, Leiden, The Netherlands).

Techniques: In Vitro, Infection, Quantitative RT-PCR